Media coverage
2
Media coverage
Title Vigeo Therapeutics To Present New Phase 1/2 VT1021 Dose Escalation And Expansion Data At The Society For Immunotherapy Of Cancer's 2020 Annual Meeting Media name/outlet TheStreet.com Country United States Date 11/9/20 Persons Devalingam Mahalingam Title Vigeo Therapeutics to Present New Phase 1/2 VT1021 Dose Escalation and Expansion Data at the Society for Immunotherapy of Cancer's 2020 Annual Meeting; 75% of Patients Who Achieved a Partial Response or Stable Disease Had High Expression of Both CD47 and Media name/outlet PR Newswire Country United States Date 11/9/20 Persons Devalingam Mahalingam